Skip to main content
Top
Published in: Cancer Immunology, Immunotherapy 1/2016

01-01-2016 | Meeting Report

“Cancer Bio-Immunotherapy in Siena”: Twelfth Meeting of the Network Italiano per la Bioterapia dei Tumori (NIBIT), Siena, Italy, October 9–11, 2014

Authors: Michele Maio, Erica Bertocci, Lorenzo Pilla, Carolina Fazio, Carla Chiarucci, Ornella Cutaia, Ester Fonsatti, Cristina Maccalli, Giorgio Parmiani, NIBIT

Published in: Cancer Immunology, Immunotherapy | Issue 1/2016

Login to get access

Excerpt

Cancer immunotherapy has gained a major breakthrough providing novel cancer treatments with high clinical efficacy. The twelfth annual meeting of the Italian Network for Tumor Bio-immunotherapy (NIBIT), organized in cooperation with the NIBIT Foundation, convened in the scenic Tuscan town of Siena with the goal of bringing together leaders in the field of immunotherapy to discuss their recent findings. Moreover, the meeting hosted young investigators presenting their own work. The following topics were discussed in this meeting: (1) mutated antigens and adoptive cell therapy in the clinics; (2) targeting cancer stem cells for immunotherapy; (3) tumor microenvironment and metabolism; (4) new developments in immune oncology; (5) vaccines: pitfalls and promises; (6) checkpoint blockade and targeted therapies in melanoma and other tumors; (7) prognostic and predictive biomarkers in bio-immunotherapy; and (8) ongoing and prospective NIBIT activities and collaborations. …
Appendix
Available only for authorised users
Metadata
Title
“Cancer Bio-Immunotherapy in Siena”: Twelfth Meeting of the Network Italiano per la Bioterapia dei Tumori (NIBIT), Siena, Italy, October 9–11, 2014
Authors
Michele Maio
Erica Bertocci
Lorenzo Pilla
Carolina Fazio
Carla Chiarucci
Ornella Cutaia
Ester Fonsatti
Cristina Maccalli
Giorgio Parmiani
NIBIT
Publication date
01-01-2016
Publisher
Springer Berlin Heidelberg
Published in
Cancer Immunology, Immunotherapy / Issue 1/2016
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI
https://doi.org/10.1007/s00262-015-1699-z

Other articles of this Issue 1/2016

Cancer Immunology, Immunotherapy 1/2016 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine